Loading the security overview…
Where the tokens are
Standardised from the company’s filings, newest period first, labelled with the company’s own fiscal calendar. A line the company does not report is left off rather than shown as zero; margins and free cash flow are worked out here, and only where every input is present.
| Line item | Q2 FY262026-06-30 | Q1 FY262026-03-31 | Q4 FY252025-12-31 | Q3 FY252025-09-30 | Q2 FY252025-06-30 | Q1 FY252025-03-31 | Q4 FY242024-12-31 | Q3 FY242024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.37B | $1.37B | $1.14B | $1.14B | $1.24B | $1.19B | $1.02B | $1.03B |
| Cost of revenue | $570.00M | $586.00M | $555.00M | $530.00M | $528.00M | $509.00M | $501.00M | $492.00M |
| Gross profit | $798.00M | $785.00M | $589.00M | $607.00M | $713.00M | $684.00M | $519.00M | $538.00M |
| Gross margin | 58.3% | 57.3% | 51.5% | 53.4% | 57.5% | 57.3% | 50.9% | 52.2% |
| Research and development | $92.00M | $97.00M | $93.00M | $89.00M | $92.00M | $94.00M | $81.00M | $87.00M |
| Selling, general and administrative | $449.00M | $381.00M | $338.00M | $351.00M | $400.00M | $341.00M | $300.00M | $323.00M |
| Operating expenses | $683.00M | $641.00M | $772.00M | $605.00M | $640.00M | $584.00M | $518.00M | $560.00M |
| Operating income | $115.00M | $144.00M | −$183.00M | $2.00M | $73.00M | $100.00M | $1.00M | −$22.00M |
| Operating margin | 8.4% | 10.5% | -16.0% | 0.2% | 5.9% | 8.4% | 0.1% | -2.1% |
| EBITDA | $295.00M | $332.00M | $193.00M | $203.00M | $243.00M | $270.00M | $172.00M | $165.00M |
| Interest expense | −$59.00M | −$57.00M | −$80.00M | −$52.00M | −$48.00M | −$40.00M | −$46.00M | −$58.00M |
| Income before taxes | $56.00M | $87.00M | −$259.00M | −$50.00M | $25.00M | $60.00M | −$51.00M | $559.00M |
| Income taxes | $2.00M | $30.00M | $17.00M | −$16.00M | $14.00M | −$7.00M | −$43.00M | $195.00M |
| Net income | $54.00M | $57.00M | −$276.00M | −$34.00M | $11.00M | $67.00M | −$8.00M | $364.00M |
| Net margin | 3.9% | 4.2% | -24.1% | -3.0% | 0.9% | 5.6% | -0.8% | 35.3% |
| EPS, basic | $0.11 | $0.11 | −$0.56 | −$0.07 | $0.02 | $0.14 | −$0.02 | $0.74 |
| EPS, diluted | $0.11 | $0.11 | −$0.56 | −$0.07 | $0.02 | $0.13 | −$0.02 | $0.73 |
| Diluted shares | 505.90M | 506.00M | 489.60M | 496.80M | 500.10M | 499.10M | 501.30M | 497.70M |
Figures describe Elanco Animal Health shares, not any token. As of Aug 5, 2026, from Massive's standardised financials. The company reports these figures; a token's issuer holds the shares and reports nothing of its own here.